Noroprobe technology enables rapid ultrasound dynamics in nanoparticles

Houston, September 6, 2021 (PRNewswire) – NuProbe scientists and collaborators have recently developed a new method for detecting somatic mutations using the Oxford Nanopore sequencing platform. The method, called Oncogen-Enhanced Enlightenment Nanopore Sequence (OCEANS), allows fast, accurate, and cost-effective analysis of somatic mutations up to 0.05% Alpha Frequency (VF). This fictional study facilitates the development of one-day, low-cost oncology panels for time-based therapy selection and follow-up. The research article September 6Th In a peer-reviewed journal Genome Biology.

“The nanopore sequence has always been attractive to scientists who are capable of providing rapid diagnosis and rapid care. In some clinical settings, we were exploring methods to implement nanopore sequences. Identify cancer mutations where speed is paramount, ”said Dr. Lawrence Kung, Assistant Professor of Translational Molecular Pathology University of Texas MD Anderson, Cancer Center and co-author of the study, said: “The proposed OCEANS method can be used to identify acute mood swings using nanoparticles and develop clinical sequencing panels on the same day and ultimately benefit patients.

Although next-generation sequencing (NS) is powerful in high-impact mutations, it can take several days to obtain results and has significant equipment and utility costs. Using the OCEANS method, the nanopore sequence improves long-term readability, short turnaround time, and low cost of equipment and consumables in many NGS approaches.

The OCEANS method uses NuProbe blocker amplification (BDA) technology to enhance low frequency frequencies and uses a new innovative Stochastic Amplicon Ligation (SAL) method to connect short DNA molecules. The OCEANS method calls for mutations and results in 100 times more sensitivity at higher results.

Using four different multi-gene OCEANS panels, the study showed that the OCEANS method can achieve VAF detection limits of 0.05% to 1% in the nanopore sequence, up to 10 hours from DNA to variables. The authors validated the OCEANS method in clinical tissue samples.

“In clinical FFPE tumor samples, this study shows more than 99% concordance from Illuminina NGS, but rapid results increase benefits.,“he said Deepak Thirunavukarasu, PhD, lead author of the study and NuProbe research scientist. This is the first peer-reviewed publication on the nanopore platform with the rapid discovery of a single nucleotide somatic mutation with low VFs.

“Accuracy and timeliness are important for clinical decision-making,“he said David Zhang, Head of Innovation at Nuprobe America, Associate Professor of Bioengineering at Rice University, And co-author of the study. “NuProbe is committed to developing technologies to enable the most sensitive products in a short period of time to assist in the accurate diagnosis and treatment of oncology.”

About NuProbe Global

Nuporobe DNA disease biomarkers are a genomics and molecular research company that has teamed up with revolutionary molecular technologies to improve the sensitivity of more than 10 times. NuProbe has sites in it Houston, America, Shanghai, China And Suzu, China. NuProbe’s vision is to provide accurate, up-to-date and accurate disease information to enable accurate treatment and improve patient outcomes.

NuProbe Owned Oncogen Enhanced Enlightenment Nanopore Sequence (OCEANS) Technology “For research use only. Not for use in diagnostic procedures. ”


Rachel Reed

Check out the original content to download multimedia:



Leave a Comment